Not only has the pandemic fuelled interest in new modalities research, but it has also triggered a renaissance of formulation approaches amongst biopharma to bring new wave of drug substances and t
An intranasal formulation of AstraZeneca's widely-used COVID-19 vaccine Vaxzevria has failed at the first hurdle, after results from a phase 1 trial found it was unable to stimulate a stron